

10 April 2018

Nick Harrison  
Listings Compliance  
Level 40, Central Park  
152-158 St Georges Terrace  
Perth WA 6000

Dear Nick

**ResApp Health Limited (“Company”) – Price Query**

We refer to your letter dated 9 April 2018 in relation to the recent increase in the Company’s share price and trading volumes and respond as follows in line with your numbering:

1. Yes, the Company is aware of information relating to its Clinical Studies (“**Information**”) that has not been announced to the market that, if known by some in the market, could explain the recent trading in its securities.

The Company also notes that it is presenting at the TechKnow Invest Conference starting today in Sydney and in Melbourne on Thursday which has historically generated keen interest in the Company.

2. (a) Yes, the Company was relying on Listing Rule 3.1A not to announce the Information under Listing Rule 3.1.  
(b) Yes, the announcement regarding the Information has been released to the market on 10 April 2018.  
(c) Not applicable.
3. Not applicable.
4. The Company confirms it is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.
5. The Company confirms that the responses to the above questions have been approved by the Board.

Yours faithfully



Nicki Farley  
Company Secretary

For personal use only



9 April 2018

Ms Nicki Farley  
Company Secretary  
ResApp Health Limited  
Level 24, 44 St George's Terrace  
PERTH WA 6000

By email:

Dear Ms Farley

**ResApp Health Limited ("RAP"): price query**

We note the change in the price of RAP's securities from a closing price of \$0.12 on 3 April 2018 to a high of \$0.18 prior to the Company's securities being placed in a trading halt today, 9 April 2018.

We also note the significant increase in the volume of RAP's securities traded during this period.

In light of this, ASX Limited ("ASX") asks RAP to respond separately to each of the following questions and requests for information:

1. Is RAP aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes":
  - a) Is RAP relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1?

Please note that the recent trading in RAP's securities would suggest to ASX that such information may have ceased to be confidential and therefore RAP may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
  - b) Can an announcement be made immediately?

Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
  - c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that RAP may have for the recent trading in its securities?
4. Please confirm that RAP is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

For personal use only

5. Please confirm that RAP's responses to the questions above have been authorised and approved in accordance with its published continuous disclosure policy or otherwise by its board or an officer of RAP with delegated authority from the board to respond to ASX on disclosure matters.

#### **When and where to send your response**

This request is made under, and in accordance with, Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by not later than **7.30 am WST tomorrow, 10 April 2018**. If we do not have your response by then, ASX will have no choice but to consider suspending trading in RAP's securities under Listing Rule 17.3.

You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, RAP's obligation is to disclose the information "immediately". This may require the information to be disclosed before the deadline set out in the previous paragraph.

ASX reserves the right to release a copy of this letter and your response on the ASX Market Announcements Platform under Listing Rule 18.7A. Accordingly, your response should be in a form suitable for release to the market.

Your response should be sent to me by e-mail at [tradinghaltspert@asx.com.au](mailto:tradinghaltspert@asx.com.au). It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

#### **Listing Rules 3.1 and 3.1A**

Listing Rule 3.1 requires a listed entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities. Exceptions to this requirement are set out in Listing Rule 3.1A.

In responding to this letter, you should have regard to RAP's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure: Listing Rules 3.1 – 3.1B*.

It should be noted that RAP's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

If you have any queries or concerns about any of the above, please contact me immediately.

Yours sincerely

*[Sent electronically without signature]*

Nick Harrison  
**Graduate, Listings Compliance**  
P: 08 9224 0000